BrainCool AB: Correction: A new clinical study with RhinoChill™ show statistically significant results- early cooling leads to improved survival and neurological function of cardiac arrest patients

Earlier today, November 18, 2019, a press release was incorrectly published citing the Market Abuse Regulation (MAR). The information in the press release is regulatory but not of a MAR nature. The full press release, without reference to MAR, can be found below.

The clinical study, presented at the American Heart meeting this weekend, was a prospectively analysis of collected data from the PRINCESS trial. It is expected to be published in a high rank medical journal this winter.

The objective of the study was to investigate investigate the association between time to initiate cooling and neurological intact survival in patients with out-of-hospital cardiac arrest. An early treatment group was defined as patients randomized by the EMS < 20 minutes from the time of the cardiac arrest. Time to randomization was used a proxy measurement for time to initiate cooling.

In patients with initial shockable rhythm ( VF/VT patients ), the difference in CPC 1-2 was 50.9% versus 29.8%, (p-value = 0.003), and in the proportion with complete recovery CPC 1 (patients with complete neurological recovery) was 47.4% versus 21.1% (p-value = 0.008).

CEO Martin Waleij comments;

-          It is clear that time to target temperature effects the results of survival and improved neurological outcome for cardiac arrest patients, in this study clearly shown in initial shockable rhythm patients.

Attached depicts a trend analysis for survival with CPC 1-2 based on how soon cooling was initiated after cardiac arrest.

For more information

Martin Waleij - CEO                                                               
+46 - 733 -93 70 76                                                                                          
E-mail: martin.waleij@braincool.se                       

About BrainCool AB (publ)

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.